Cancer Genetics (NASDAQ:CGIX) announced its earnings results on Tuesday, May 15th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03), MarketWatch Earnings reports. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.20 million. Cancer Genetics had a negative return on equity of 77.26% and a negative net margin of 52.87%.
Shares of NASDAQ CGIX traded up $0.09 during trading on Wednesday, hitting $1.05. The company had a trading volume of 19,700 shares, compared to its average volume of 217,725. The company has a market capitalization of $25.67 million, a P/E ratio of -1.33 and a beta of 1.28. Cancer Genetics has a 12 month low of $0.82 and a 12 month high of $4.35. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.03.
Several research analysts have issued reports on the company. Zacks Investment Research raised Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. ValuEngine raised Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Dawson James downgraded Cancer Genetics from a “buy” rating to a “neutral” rating in a research note on Friday, April 6th. Maxim Group downgraded Cancer Genetics from a “buy” rating to a “hold” rating and set a $6.00 price objective on the stock. in a research note on Tuesday, April 3rd. Finally, HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $5.56.
About Cancer Genetics
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.